Trump unveils TrumpRx discounted drugs website

U.S. President Donald Trump unveiled a new website called TrumpRx.gov during a White House event on Thursday, February 5, 2026, as part of a strategic initiative to slash prescription medication costs for American consumers. Flanked by CMS Administrator Dr. Mehmet Oz and Airbnb co-founder Joe Gebbia, the President introduced the platform as a tool to provide direct access to discounted drugs through "most-favored nation" deals. This policy was established to pressure pharmaceutical companies into offering lower prices in exchange for exemptions from high U.S. tariffs, aiming to bring domestic costs closer to those paid in foreign markets. The platform operates through a partnership with the savings site GoodRx, serving as a portal that redirects patients to various purchasing channels rather than selling medications directly. Significant industry players, including Eli Lilly, Novo Nordisk, Pfizer, and AstraZeneca, have joined the program. A primary focus of the launch is the reduction of prices for popular GLP-1 weight-loss drugs like Ozempic and Wegovy, with the administration claiming monthly costs could drop to between $149 and $350 for cash-paying customers. While the administration touts the website as a major victory for public health, policy experts from the KFF have raised concerns regarding its actual impact on insured citizens. Because the site targets cash-paying consumers, many purchases may not count toward insurance deductibles, leaving some medications still unaffordable for lower-income families. Despite these criticisms, pharmaceutical companies may benefit by bypassing traditional insurance middlemen and selling directly to consumers, ensuring volume even at discounted rates. In addition to obesity treatments, TrumpRx lists a variety of critical medications such as the diabetes drug Januvia, the blood thinner Plavix, and asthma inhalers. Pfizer alone has committed to providing over 30 medicines at discounted rates through the program. The initiative represents a significant shift in U.S. healthcare policy, prioritizing direct-to-consumer models and trade-based leverage to manage the rising costs of the pharmaceutical industry.